Browse > Article

Screening of Anti-atherogenic Substances from Insect Resources  

Park, Doo-Sang (Insect Resources Laboratory, Korea Research Institute of Bioscience and Biotechnology)
Yoon, Mi-Ae (Insect Resources Laboratory, Korea Research Institute of Bioscience and Biotechnology)
Xu, Ming-Zhe (Insect Resources Laboratory, Korea Research Institute of Bioscience and Biotechnology)
Yu, Ha-Na (Lipid Metabolism Research Laboratory, Korea Research Institute of Bioscience and Biotechnology)
Kim, Ju-Ryoung (Lipid Metabolism Research Laboratory, Korea Research Institute of Bioscience and Biotechnology)
Jeong, Tae-Sook (Lipid Metabolism Research Laboratory, Korea Research Institute of Bioscience and Biotechnology)
Park, Ho-Yong (Insect Resources Laboratory, Korea Research Institute of Bioscience and Biotechnology)
Publication Information
Korean Journal of Pharmacognosy / v.35, no.3, 2004 , pp. 233-238 More about this Journal
Abstract
Lipoprotein-associated phospholipase $A_2\;(Lp-PLA_2)$ is a potential biomarker of coronary heart disease and plays an important proinflammatory role in the progression of atherosclerosis. Also acyl-CoA: cholesterol acyltransferase (ACAT) and oxidized low-density lipoprotein (LDL) playa key role in atherosclerosis, respectively. And so, the inhibitory activities of the methanol extracts of 42 insect resources were examined on $Lp-PLA_2$, ACAT, and LDL oxidation for screening of anti-atherogenic substances. Among them, the methanol extracts of Eurydema rugosa significantly inhibited all of upper three activities. Several kinds of tested insects having high inhibitory effect with the methanol extracts were extracted with n-hexane, ethyl acetate, and acetone, and their inhibitory activities were tested.
Keywords
$Lp-PLA_2$; ACAT; LDL-oxidation; inhibitor; atherosclerosis; insect resources;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Glass, C. K. and Witztum, J. L. (2001) Atherosclerosis: The road ahead. Cell 104: 503-516   DOI   ScienceOn
2 Buhman, K. K., Accad, M., Novak, S., Choi, R. S., Wong, J. S., Hamilton, R. L., Turley, S., and Farese, R. V. Jr. (2000) Resistance to diet-induced hypercholesterolemia and gallstone formation in ACAT2-deficient mice. Nautre Med. 6: 1341-1347   DOI   ScienceOn
3 Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248254   DOI   PUBMED   ScienceOn
4 Jeong, T. S., Kim, S. U., Son, K. H., Kwon, B. M., Kim, Y. K., Choi, M. D., a,nd Bok, S. H. (1995) GERI-BPOOI compounds, new inhibitors of Acyl-CoA:cholesterol acyltransferase from Aspergillus fumigatus F37. I. Production, isolation, and physico-chemical and biological properties. J. Antibiotics 48: 751-756   DOI   ScienceOn
5 Xu, M.-Z., Lee, W. S., Kim, M. J., Park, D.-S., Yu, H., Tian, G.-R., Jeong, T.-S., and Park, H.-Y. (2004) Acyl-CoA: cholesterol acyltransferase inhibitory activities of fatty acid arnides isolated from Mylabris phalerate Pallas Bioorg. Med. Chem. Lett., 14: 4277-4280   DOI   ScienceOn
6 Jessup, W. and Kritharides L. (2000) Metabolism of oxidized LDL by macrophages. Curro Opin. lipidol., 11: 473-481   DOI   ScienceOn
7 Suckling, E. S. and Macphee, C. H. (2002) Lipoproteinassociated phospholipase $A_2$: a tagget directed at the atheroslcerotic plaque. Expert Opin. Ther. Targets 6: 309-413   DOI   ScienceOn
8 Packard, C. J., O'Reilly, S. J., Caslake, M. J., McMahon, A. D., Ford, I., Cooney, J., Macphee, C. H., Suckling, K E., Krishna, M., Wilkinson, F. E., Rumley, A. and Lowe. G. D. O. (2000) Lipoprotein associated phospholipase A2 asindependent predictor of coronarY heart disease. N. Engl. 1. Med. 343: 1148-1155   DOI   ScienceOn
9 Accad, M., Smith S. J., Newland, D. L., Sanan, D. A, King, L. E. Jr, Linton, M. F, Fazio, S., and Farese, R. V. Jr. (2000) Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA:cholesterol acyltransferase 1. J. Clin. Invest. 105: 711-719   DOI   ScienceOn
10 Havel, R. J., Edger, H. A, and Bradgon, J. H. (1955) The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34: 1345-1353   DOI   ScienceOn
11 Ahn, B. T., Lee, S., Lee, S. B., Lee, E. S., Kim, J. G., Bok, S. H., and Jeong, T. S. (2001) Low-density lipoprotein-antioxidant constituents of Saururus chinensis. J. Nat. Prod. 64: 1562-1564   DOI   ScienceOn
12 Macphee, C. H. (2001) Lipoprotein-associated phospholipase $A_2$: a potential new risk factor for coronary qrtery disease and a therapeutic target. Curro Opin. Pharmacol. 1: 121: a potential new risk factor for coronary qrtery disease and a therapeutic target. Curro Opin. Pharmacol. 1: 121-125   DOI   PUBMED   ScienceOn
13 Hurt-Camejo, E., Camejo, G., Peilot, H., Oomi, K., and Kovanen, P. Phospholipase $A_2$ in vascular disease. (2001) Circ. Res. 89: 298-304   DOI   ScienceOn
14 Ross, R. (1999) Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340: 233-241
15 Chang, T. Y., Chang, C. C. Y., and Cheng, D. (1997) Acylcoenzyme A : cholesterol acyltransferase. Annu. Rev. Biochem. 66: 613-638   DOI   ScienceOn
16 Bloomer, J. C., Boyd, H. F, Hickey, D. M. B., Ife, R. J., Leach, C. A, Macphee, C. H., Miller, K J., Pinto, I. L., Rawlings, D. A, Smith, S. A., et al. (2001) 1-(arylpiperazinylarnidoalkyl)-pyrimidones: orally active inhibitors of lipoprotein-assiciated phospholipase $A_2$. Bioorg. Med. Chem. Lett., 11:1925-1929   DOI   ScienceOn
17 Lusis, A. J. (2000) Atherosclerosis. Nature 407: 233-241   DOI   PUBMED   ScienceOn
18 Bays, H. and Stein, E. A. Pharmacotherapy for dyslipidemia - current therapies and future agents. (2003) Expert Opin. Pharmacother. 4: 1901-1938   DOI   ScienceOn
19 Bjorkhem, I., Henriksson-Freyschuss, A, Breuer, O., Diczfalusy, U. Berglund, L., and Henriksson, P. (1991) The antioxidant butylated hydroxytoluene protects against atherosclerosis. Arterioscler. Thromb. 11: 15-22   DOI   PUBMED
20 Erickson, S. K., Shrewsbury, M. A, Brooks, C., and Meyer, D. J. (1980) Rat liver acyl coemzyme A:cholesterol acyltransferase: its regulation in vivo and some of its properties in vitro. J. Lipid Res. 21: 930-941
21 Brecher, P. and Chan, C. (1980) Properties of Acyl-CoA : Chdlesteml acyltransflitase in aortic rrlittosomcs froth atherosclerotic rabbit. Biochim. Biophys. Acta 617: 458-471   DOI   ScienceOn
22 Prescott, S. M., Zimmerman, G. A, Stafforini, D. M., and Mcintyre, T. M. (2000) Platelet activating factor and related lipid mediators. Ann. Rev.' Biochem. 69: 419-445   DOI   ScienceOn
23 MacPhee, C. H., Moores, K. E., Boyd, H. F., Dhanak, D., Ife, R. J., Leach, C. A, Leake, D. S., Milliner, K. J., Patterson, R. A, Suckling, K. E., 'few, D. G., and Hickey, D. M. (1999) Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. J. Biochem. 338: 479-487   DOI   ScienceOn
24 Cho, K H., An, S. J., Lee, W. S., Paik, Y. K, Kim, Y. K., and Jeong. T. S. (2003) ;Mass-production of human ACAT-l and ACAT-2 to screen isoform-specific inhibitor: a different substrate specificity and inhibitory regulation. Biochem. Biophysic. Res. Comm. 309: 864-872   DOI   ScienceOn
25 Yu, H. N., Sok, D. E., and Jeong, T. S. (2003) Inhibitory effects of natural plant extracts on lipoprotein-associated phospholipase Az inhibitor. Kor. J. Pharmacogn. 34: 100-108
26 Boyd, H. F, Fell, S. C. M., Flynn, S. T., Hickey, D. M. B., life, R. J., Leach, C. A, Macphee, C. H., Milliner, K J., Moores, K. E., Pinto, I. L. (2002) N-l substituted pyrimidine-4-ones: novel, orally active inhibitors of lipoprotein-associated phospholipase $A_2$Bioorg. Med. Chem. Lett., 10: 2557-2561   DOI   ScienceOn
27 Rudel, L. L. (2001) Acyl coenzyme A:cholesterol acyltransferade type 1 and 2 : structure and function in atherosclerosis. Curro opin. lipidol. 12: 121-127   DOI   ScienceOn
28 Steinberg, D.; Parthasarathy, S.; Carew, T. E.; Khoo, J. C.; Witztum, J. L. (1989) Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 1989, 320, 915-924   DOI   ScienceOn